Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection. Issue 4 (3rd April 2018)

• Record Type: Journal Article
• Authors: Zurek Munk-Madsen, Maria; Toft, Lars; Kube, Tina; Richter, Rolf; Ostergaard, Lars; Søgaard, Ole S.; Tolstrup, Martin; Kaufmann, Andreas M.
• Is Part Of: Human vaccines & immunotherapeutics. Volume 14:Issue 4(2018)
• Page Start: 909
• Page End: 916
• Publication Date: 2018-04-03
• Subjects: cell mediated immunity -- human papillomavirus vaccines -- hiv -- vaccinology -- T helper cell response; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2017.1407896
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Human papillomavirus (HPV) infection is a frequent cause of malignant and non-malignant disease, in particular among persons with HIV. HPV serotype-specific anti L1 antibodies protect against HPV infection but little is known about prophylactic HPV vaccine-induced cell-mediated immunity against HPV in high-risk individuals. We recently showed that both HPV vaccines (Gardasil® and Cervarix®) induce solid, serological immune responses in HIV-infected persons. This study aimed to characterize HPV-specific CD4 T cells in HIV-infected HPV-vaccine recipients, T cell responses being critical for B cell activation and antibody-isotype switching. Thirty HIV-infected patients on long-term antiretroviral treatment (ART) received 3 doses of either Cervarix (n = 15) or Gardasil (n = 15) vaccine at month 0, 1.5 and 6. Cryopreserved peripheral blood mononuclear cells (PBMC) from baseline, 7 and 12 months were subjected to 24-hour stimulation with specific pools of HPV L1-peptides (HPV6, 11, 16, 18, 31 and 45) and HPV E6/E7-peptide pools (HPV6/11 and HPV16/18). Fluorescence-activated cell sorting with intracellular staining (IC-FACS) against CD4, CD154, IL-2, and IFNγ was performed. Frequencies (%) of HPV-antigen specific CD4+ T cells (CD154 + /IL-2 + or CD154 + / IFNγ + ) were determined. Both HPV-vaccines significantly and comparably enhanced cell-mediated vaccine L1 antigen-specific immunity in HIV-positive adults receiving ART therapy at month 7 and 12 after first vaccine dose. This suggests that the vaccines induce CD4 T cellular memory despite HIV-induced immune compromisation.